Single-Anastomosis Sleeve Jejunal Bypass for the Treatment of Morbid Obesity: A Surgeon's Experiential Insights

Abstract

Background:

The surge in morbid obesity has propelled innovations in bariatric procedures. This study evaluated the clinical outcomes, safety, and efficacy of single-anastomosis sleeve jejunal (SASJ) bypass.

Methods:

In this prospective multicenter study, 175 patients who underwent SASJ bypass for morbid obesity between February 2018 and December 2022 in Baghdad were enrolled and followed up for 2 years. The inclusion criteria were body mass index (BMI) 35–39.9 kg/m² with obesity-associated medical problems (OAMPs) or BMI >40 kg/m². A single surgical team ensured consistency and performed preoperative biochemical and radiological assessments.

Results:

Patients were 18–55 years of age; 70.28% were female. Their weight and BMI were 85–190 kg and 37–58 kg/m², respectively. Postoperative average weight loss was 79.2 ± 9.7 kg, and BMI decreased to 28.2 ± 3.9 kg/m² over 2 years. Excess and total weight loss percentages were 70.1% ± 13.1% and 41.9% ± 7.9%, respectively. Remission rates for OAMPs were: diabetes (95.4%), hypertension (91.02%), hyperlipidemia (95.59%), sleep apnea (100%), and gastroesophageal reflux disease (82.61%). Manageable complications included diarrhea, hair loss, and vomiting.

Conclusion:

The significant postoperative weight loss and remission rates for OAMPs highlight the effectiveness and health impacts of SASJ bypass. Personalized care, monitoring, and understanding postoperative complications are vital for positive outcomes.